APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Bacterial Vaginosis OTC Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Bacterial Vaginosis OTC Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173969050319 December 2025194 pages

Choose your research edition.

Industry ResearchBacterial Vaginosis OTC Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Bacterial Vaginosis OTC Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Bacterial Vaginosis OTC Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bacterial Vaginosis OTC Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Bacterial Vaginosis OTC Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Bacterial Vaginosis OTC Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Bacterial Vaginosis OTC Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bacterial Vaginosis OTC Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bacterial Vaginosis OTC Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Bacterial Vaginosis OTC Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Bacterial Vaginosis OTC Drug include Abbott, Teva, Sanofi, Pfizer, Bayer, Yunnan Baiyao, Xiuzheng, West-Ward and Starpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bacterial Vaginosis OTC Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bacterial Vaginosis OTC Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bacterial Vaginosis OTC Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bacterial Vaginosis OTC Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Bacterial Vaginosis OTC Drug Segment by Company

Abbott

Teva

Sanofi

Pfizer

Bayer

Yunnan Baiyao

Xiuzheng

West-Ward

Starpharma

Piramal

Perrigo

Novel

Mission

HPGC

Galderma

Edenvridge

Alkem

Bacterial Vaginosis OTC Drug Segment by Type

Pill

Cream

Gel

Other

Bacterial Vaginosis OTC Drug Segment by Application

Pharmacy

On-line

Other

Bacterial Vaginosis OTC Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacterial Vaginosis OTC Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bacterial Vaginosis OTC Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bacterial Vaginosis OTC Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bacterial Vaginosis OTC Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Bacterial Vaginosis OTC Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Bacterial Vaginosis OTC Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Bacterial Vaginosis OTC Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Bacterial Vaginosis OTC Drug Industry Trends Table 2. Bacterial Vaginosis OTC Drug Industry Drivers Table 3. Bacterial Vaginosis OTC Drug Industry Opportunities and Challenges Table 4. Bacterial Vaginosis OTC Drug Industry Restraints Table 5. Global Bacterial Vaginosis OTC Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Bacterial Vaginosis OTC Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Bacterial Vaginosis OTC Drug Sales Market Share by Manufacturers Table 9. Global Bacterial Vaginosis OTC Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Bacterial Vaginosis OTC Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Bacterial Vaginosis OTC Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Bacterial Vaginosis OTC Drug Manufacturers, Product Type & Application Table 13. Global Bacterial Vaginosis OTC Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Bacterial Vaginosis OTC Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pill Table 17. Major Manufacturers of Cream Table 18. Major Manufacturers of Gel Table 19. Major Manufacturers of Other Table 20. Global Bacterial Vaginosis OTC Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Bacterial Vaginosis OTC Drug Sales by Type (2021-2026) & (K Units) Table 22. Global Bacterial Vaginosis OTC Drug Sales by Type (2027-2032) & (K Units) Table 23. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2021-2026) Table 24. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2027-2032) Table 25. Global Bacterial Vaginosis OTC Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Bacterial Vaginosis OTC Drug Revenue by Type (2021-2026) & (K Units) Table 27. Global Bacterial Vaginosis OTC Drug Revenue by Type (2027-2032) & (K Units) Table 28. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2021-2026) Table 29. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Pharmacy Table 31. Major Manufacturers of On-line Table 32. Major Manufacturers of Other Table 33. Global Bacterial Vaginosis OTC Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Bacterial Vaginosis OTC Drug Sales by Application (2021-2026) & (K Units) Table 35. Global Bacterial Vaginosis OTC Drug Sales by Application (2027-2032) & (K Units) Table 36. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2021-2026) Table 37. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2027-2032) Table 38. Global Bacterial Vaginosis OTC Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Bacterial Vaginosis OTC Drug Revenue by Application (2021-2026) & (K Units) Table 40. Global Bacterial Vaginosis OTC Drug Revenue by Application (2027-2032) & (K Units) Table 41. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2021-2026) Table 42. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2027-2032) Table 43. Global Bacterial Vaginosis OTC Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Bacterial Vaginosis OTC Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2021-2026) Table 46. Global Bacterial Vaginosis OTC Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Bacterial Vaginosis OTC Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 50. North America Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 51. Europe Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 53. Europe Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Bacterial Vaginosis OTC Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Bacterial Vaginosis OTC Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Bacterial Vaginosis OTC Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2021-2026) Table 64. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2027-2032) Table 65. Abbott Company Information Table 66. Abbott Business Overview Table 67. Abbott Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Abbott Bacterial Vaginosis OTC Drug Product Portfolio Table 69. Abbott Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva Bacterial Vaginosis OTC Drug Product Portfolio Table 74. Teva Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanofi Bacterial Vaginosis OTC Drug Product Portfolio Table 79. Sanofi Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer Bacterial Vaginosis OTC Drug Product Portfolio Table 84. Pfizer Recent Development Table 85. Bayer Company Information Table 86. Bayer Business Overview Table 87. Bayer Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Bayer Bacterial Vaginosis OTC Drug Product Portfolio Table 89. Bayer Recent Development Table 90. Yunnan Baiyao Company Information Table 91. Yunnan Baiyao Business Overview Table 92. Yunnan Baiyao Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Yunnan Baiyao Bacterial Vaginosis OTC Drug Product Portfolio Table 94. Yunnan Baiyao Recent Development Table 95. Xiuzheng Company Information Table 96. Xiuzheng Business Overview Table 97. Xiuzheng Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Xiuzheng Bacterial Vaginosis OTC Drug Product Portfolio Table 99. Xiuzheng Recent Development Table 100. West-Ward Company Information Table 101. West-Ward Business Overview Table 102. West-Ward Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. West-Ward Bacterial Vaginosis OTC Drug Product Portfolio Table 104. West-Ward Recent Development Table 105. Starpharma Company Information Table 106. Starpharma Business Overview Table 107. Starpharma Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Starpharma Bacterial Vaginosis OTC Drug Product Portfolio Table 109. Starpharma Recent Development Table 110. Piramal Company Information Table 111. Piramal Business Overview Table 112. Piramal Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Piramal Bacterial Vaginosis OTC Drug Product Portfolio Table 114. Piramal Recent Development Table 115. Perrigo Company Information Table 116. Perrigo Business Overview Table 117. Perrigo Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Perrigo Bacterial Vaginosis OTC Drug Product Portfolio Table 119. Perrigo Recent Development Table 120. Novel Company Information Table 121. Novel Business Overview Table 122. Novel Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Novel Bacterial Vaginosis OTC Drug Product Portfolio Table 124. Novel Recent Development Table 125. Mission Company Information Table 126. Mission Business Overview Table 127. Mission Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Mission Bacterial Vaginosis OTC Drug Product Portfolio Table 129. Mission Recent Development Table 130. HPGC Company Information Table 131. HPGC Business Overview Table 132. HPGC Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. HPGC Bacterial Vaginosis OTC Drug Product Portfolio Table 134. HPGC Recent Development Table 135. Galderma Company Information Table 136. Galderma Business Overview Table 137. Galderma Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Galderma Bacterial Vaginosis OTC Drug Product Portfolio Table 139. Galderma Recent Development Table 140. Edenvridge Company Information Table 141. Edenvridge Business Overview Table 142. Edenvridge Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Edenvridge Bacterial Vaginosis OTC Drug Product Portfolio Table 144. Edenvridge Recent Development Table 145. Alkem Company Information Table 146. Alkem Business Overview Table 147. Alkem Bacterial Vaginosis OTC Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Alkem Bacterial Vaginosis OTC Drug Product Portfolio Table 149. Alkem Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Bacterial Vaginosis OTC Drug Distributors List Table 153. Bacterial Vaginosis OTC Drug Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Bacterial Vaginosis OTC Drug Product Image Figure 2. Global Bacterial Vaginosis OTC Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bacterial Vaginosis OTC Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Bacterial Vaginosis OTC Drug Sales (2021-2032) & (K Units) Figure 5. Global Bacterial Vaginosis OTC Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Bacterial Vaginosis OTC Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pill Image Figure 9. Cream Image Figure 10. Gel Image Figure 11. Other Image Figure 12. Global Bacterial Vaginosis OTC Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Bacterial Vaginosis OTC Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2021-2032) Figure 15. Global Bacterial Vaginosis OTC Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Bacterial Vaginosis OTC Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2021-2032) Figure 18. Pharmacy Image Figure 19. On-line Image Figure 20. Other Image Figure 21. Global Bacterial Vaginosis OTC Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Bacterial Vaginosis OTC Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2021-2032) Figure 24. Global Bacterial Vaginosis OTC Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Bacterial Vaginosis OTC Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 41. China Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Bacterial Vaginosis OTC Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Bacterial Vaginosis OTC Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Bacterial Vaginosis OTC Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Bacterial Vaginosis OTC Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Bacterial Vaginosis OTC Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Bacterial Vaginosis OTC Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Bacterial Vaginosis OTC Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Pill
  • Cream
  • Gel
  • Other
Applications
  • Pharmacy
  • On-line
  • Other
Companies covered
  • Abbott
  • Teva
  • Sanofi
  • Pfizer
  • Bayer
  • Yunnan Baiyao
  • Xiuzheng
  • West-Ward
  • Starpharma
  • Piramal
  • Perrigo
  • Novel
  • Mission
  • HPGC
  • Galderma
  • Edenvridge
  • Alkem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Bacterial Vaginosis OTC Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Bacterial Vaginosis OTC Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Bacterial Vaginosis OTC Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Bacterial Vaginosis OTC Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Bacterial Vaginosis OTC Drug Market Dynamics
  1. 2.1 Bacterial Vaginosis OTC Drug Industry Trends
  2. 2.2 Bacterial Vaginosis OTC Drug Industry Drivers
  3. 2.3 Bacterial Vaginosis OTC Drug Industry Opportunities and Challenges
  4. 2.4 Bacterial Vaginosis OTC Drug Industry Restraints
3 Bacterial Vaginosis OTC Drug Market by Manufacturers
  1. 3.1 Global Bacterial Vaginosis OTC Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Bacterial Vaginosis OTC Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Bacterial Vaginosis OTC Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Bacterial Vaginosis OTC Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Bacterial Vaginosis OTC Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Bacterial Vaginosis OTC Drug Manufacturers, Product Type & Application
  7. 3.7 Global Bacterial Vaginosis OTC Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Bacterial Vaginosis OTC Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Bacterial Vaginosis OTC Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Bacterial Vaginosis OTC Drug Tier 1, Tier 2, and Tier 3
4 Bacterial Vaginosis OTC Drug Market by Type
  1. 4.1 Bacterial Vaginosis OTC Drug Type Introduction
  2. 4.1.1 Pill
  3. 4.1.2 Cream
  4. 4.1.3 Gel
  5. 4.1.4 Other
  6. 4.2 Global Bacterial Vaginosis OTC Drug Sales by Type
  7. 4.2.1 Global Bacterial Vaginosis OTC Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Bacterial Vaginosis OTC Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Bacterial Vaginosis OTC Drug Revenue by Type
  11. 4.3.1 Global Bacterial Vaginosis OTC Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Bacterial Vaginosis OTC Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2021-2032)
5 Bacterial Vaginosis OTC Drug Market by Application
  1. 5.1 Bacterial Vaginosis OTC Drug Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 On-line
  4. 5.1.3 Other
  5. 5.2 Global Bacterial Vaginosis OTC Drug Sales by Application
  6. 5.2.1 Global Bacterial Vaginosis OTC Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bacterial Vaginosis OTC Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Bacterial Vaginosis OTC Drug Revenue by Application
  10. 5.3.1 Global Bacterial Vaginosis OTC Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Bacterial Vaginosis OTC Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2021-2032)
6 Global Bacterial Vaginosis OTC Drug Sales by Region
  1. 6.1 Global Bacterial Vaginosis OTC Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bacterial Vaginosis OTC Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Bacterial Vaginosis OTC Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Bacterial Vaginosis OTC Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Bacterial Vaginosis OTC Drug Revenue by Region
  1. 7.1 Global Bacterial Vaginosis OTC Drug Revenue by Region
  2. 7.1.1 Global Bacterial Vaginosis OTC Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Bacterial Vaginosis OTC Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Bacterial Vaginosis OTC Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Bacterial Vaginosis OTC Drug Revenue (2021-2032)
  8. 7.2.2 North America Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Bacterial Vaginosis OTC Drug Revenue (2021-2032)
  11. 7.3.2 Europe Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Bacterial Vaginosis OTC Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Bacterial Vaginosis OTC Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Bacterial Vaginosis OTC Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Bacterial Vaginosis OTC Drug Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Bacterial Vaginosis OTC Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Bacterial Vaginosis OTC Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Bacterial Vaginosis OTC Drug Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Bacterial Vaginosis OTC Drug Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Yunnan Baiyao
  32. 8.6.1 Yunnan Baiyao Company Information
  33. 8.6.2 Yunnan Baiyao Business Overview
  34. 8.6.3 Yunnan Baiyao Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Yunnan Baiyao Bacterial Vaginosis OTC Drug Product Portfolio
  36. 8.6.5 Yunnan Baiyao Recent Developments
  37. 8.7 Xiuzheng
  38. 8.7.1 Xiuzheng Company Information
  39. 8.7.2 Xiuzheng Business Overview
  40. 8.7.3 Xiuzheng Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Xiuzheng Bacterial Vaginosis OTC Drug Product Portfolio
  42. 8.7.5 Xiuzheng Recent Developments
  43. 8.8 West-Ward
  44. 8.8.1 West-Ward Company Information
  45. 8.8.2 West-Ward Business Overview
  46. 8.8.3 West-Ward Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 West-Ward Bacterial Vaginosis OTC Drug Product Portfolio
  48. 8.8.5 West-Ward Recent Developments
  49. 8.9 Starpharma
  50. 8.9.1 Starpharma Company Information
  51. 8.9.2 Starpharma Business Overview
  52. 8.9.3 Starpharma Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Starpharma Bacterial Vaginosis OTC Drug Product Portfolio
  54. 8.9.5 Starpharma Recent Developments
  55. 8.10 Piramal
  56. 8.10.1 Piramal Company Information
  57. 8.10.2 Piramal Business Overview
  58. 8.10.3 Piramal Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Piramal Bacterial Vaginosis OTC Drug Product Portfolio
  60. 8.10.5 Piramal Recent Developments
  61. 8.11 Perrigo
  62. 8.11.1 Perrigo Company Information
  63. 8.11.2 Perrigo Business Overview
  64. 8.11.3 Perrigo Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Perrigo Bacterial Vaginosis OTC Drug Product Portfolio
  66. 8.11.5 Perrigo Recent Developments
  67. 8.12 Novel
  68. 8.12.1 Novel Company Information
  69. 8.12.2 Novel Business Overview
  70. 8.12.3 Novel Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novel Bacterial Vaginosis OTC Drug Product Portfolio
  72. 8.12.5 Novel Recent Developments
  73. 8.13 Mission
  74. 8.13.1 Mission Company Information
  75. 8.13.2 Mission Business Overview
  76. 8.13.3 Mission Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mission Bacterial Vaginosis OTC Drug Product Portfolio
  78. 8.13.5 Mission Recent Developments
  79. 8.14 HPGC
  80. 8.14.1 HPGC Company Information
  81. 8.14.2 HPGC Business Overview
  82. 8.14.3 HPGC Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 HPGC Bacterial Vaginosis OTC Drug Product Portfolio
  84. 8.14.5 HPGC Recent Developments
  85. 8.15 Galderma
  86. 8.15.1 Galderma Company Information
  87. 8.15.2 Galderma Business Overview
  88. 8.15.3 Galderma Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Galderma Bacterial Vaginosis OTC Drug Product Portfolio
  90. 8.15.5 Galderma Recent Developments
  91. 8.16 Edenvridge
  92. 8.16.1 Edenvridge Company Information
  93. 8.16.2 Edenvridge Business Overview
  94. 8.16.3 Edenvridge Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Edenvridge Bacterial Vaginosis OTC Drug Product Portfolio
  96. 8.16.5 Edenvridge Recent Developments
  97. 8.17 Alkem
  98. 8.17.1 Alkem Company Information
  99. 8.17.2 Alkem Business Overview
  100. 8.17.3 Alkem Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Alkem Bacterial Vaginosis OTC Drug Product Portfolio
  102. 8.17.5 Alkem Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bacterial Vaginosis OTC Drug Value Chain Analysis
  2. 9.1.1 Bacterial Vaginosis OTC Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bacterial Vaginosis OTC Drug Production Mode & Process
  6. 9.2 Bacterial Vaginosis OTC Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bacterial Vaginosis OTC Drug Distributors
  9. 9.2.3 Bacterial Vaginosis OTC Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst